Vemurafenib is an orally active diaryl-sulfonamide that selectively blocks v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E kinase, halting mitogen-activated protein kinase signaling and inducing autophagy in mutation-positive melanoma.
Usually ships within 24 hours.